Pancreatic Neuroendocrine Tumors: A Narrative Review - 30/03/26
, Manuelita Pardo-Ortiz 2, 3, 4
, Raul Antonio Cañadas 2, 3, 4, 5
, Leonardo Rojas-Melo 3, 6
, Dario Parra-Prieto 3, 6 
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Highlights in Pancreatic Neuroendocrine Tumors |
• | CgA is the most useful general biomarker, but lacks diagnostic specificity. |
• | Small non-functional pNETs (<2 cm) can be safely surveilled in selected cases. |
• | Ga-68 PET/CT offers superior sensitivity and is essential for staging and PRRT. |
• | Targeted therapy (everolimus, sunitinib) improves PFS in advanced pNETs. |
• | EUS-RFA is effective for small pNETs in non-surgical candidates (≈96% response). |
Abstract |
Pancreatic neuroendocrine tumors (pNET) are rare neoplasms with variable clinical behavior. Their classification is based on hormonal functionality and genetic context, being divided into functional and non-functional tumors, as well as sporadic and hereditary. Diagnosis requires a comprehensive approach that includes hormonal studies, molecular markers, imaging and histopathological evaluation. Staging, based on systems such as AJCC and ENETS, guides therapeutic decisions, ranging from surgical resection to systemic therapy and radionuclides. This review presents a critical synthesis of the latest evidence on epidemiology, pathophysiology, diagnosis, classification, biomarkers, staging and treatment of pNETs.
Le texte complet de cet article est disponible en PDF.Key words : pancreatic neuroendocrine tumor, biomarkers, staging, targeted therapy, functional tumors
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
